Kimitsu Chuo Hospital

Kisarazu, Chiba 292-8535

0 studies enrolling now · 4 studies all time

What they study most

Abiraterone Acetate, Acute Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, Androgens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Atrial Fibrillation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cytochrome P-450, Enzyme Inhibitors, High-risk Transient Ischemic Attack

Studies at this site

• A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke — Completed
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) — Running, not enrolling
• A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early